Blog
Background Investigation Methods, Corporate Intelligence & Due Diligence, e-Discovery Techniques, Investigation & Intelligence Feeds, Judgment Enforcement, Legal Enforcement Cases, Legal Ethics & Intelligence, Legal Technology & Intelligence, Witness Credibility Analysis
In re Entresto (sacubitril/valsartan) Patent Litigation (Novartis Pharms. Corp. v. MSN Pharms. Inc.)
Nature of the Case and Issue(s) Presented: Novartis holds the NDA for Entresto, a drug used to treat heart failure, having the active ingredients sacubitril and valsartan. The ’918 patent is not an Orange Book-listed patent and claims the chemical compound that comprised Entresto, which is an amorphous solid form of sacubitril, valsartan, and sodium cations (“Amorphous TVS”). The priority date of the ’918 patent is April 4, 2006….
By: Robins Kaplan LLP